Sovereign Mirror · Ghana · Health Financing — Marginal Allocation 2026–28
Ministry of Finance Run 3 · Comprehensive 22/22 VERIDEX April 2026
The Question Under Analysis Confirmed April 2026 · Sovereign Mirror v1.0 · Run 3
Allocation Question
How should the marginal public health financing dollar available to the Ghana Ministry of Health be allocated across 2026–2028, given the NHIL uncapping, the 120% tariff revision, the functional orphaning of Agenda 111, and a documented rise in catastrophic health expenditure from 1.26% (2012) to 11.45% (2023) — despite two decades of NHIS operation?
a
NHIL uncapping (March 2025) restored NHIA revenue from GH¢6.52bn (2024) to GH¢9.76bn (2025 actual), with GH¢11.416bn programmed for NHIF in 2026 — the most significant health financing reform in 22 years.
b
120% average tariff increase effective January 2026. NHIA Deputy CEO estimates ~180% rise in total claims. Projected 2026 funding gap: GH¢4.9–8.7bn against GH¢9.037bn NHIS operations allocation.
c
Agenda 111 functionally orphaned. Zero hospitals operational. US$400m spent. Completion cost: US$1.589bn. 2026 allocation: GH¢100m for 10 sites. PPP/FBO pivot February 2026.
d
CHPS network ~50% functional — 5,062 zones, ~2,539 CHO deficit, 21% recurrent under-investment. PHC benefit-cost ratio: 7.2–11.3x (Lancet Commission 2022) to 16:1 (World Bank EAP 2026).
e
CHE worsened from 1.26% (2012) to 11.45% (2023) at the 10% threshold — driven by medicines and inpatient care outside NHIS coverage — despite two decades of insurance operation.
f
Ghana Medical Trust Fund (GMTF/MahamaCares, Act 1144) operational with GH¢2.9bn for 2026 — carving NCD/specialist costs out of the core NHIS envelope, creating a new structural boundary.
Binding Constraints — Exchange 4 (7 confirmed)
1
GMTF boundary fixed — GH¢2.9bn not available for reallocation to CHPS or NHIS operations.
2
Agenda 111 pure-public-fiscal option closed — PPP/FBO pivot effective February 2026. Appears in Counterfactual Pause only.
3
IMF ECF primary surplus anchor binding — total MoH envelope growth constrained; marginal allocation is within-envelope reallocation.
4
NHIL uncapping is the baseline — already implemented March 2025; not an option under analysis.
5
GHF/GSF sovereign wealth recapitalisation off the table — Ghana has explicitly chosen the earmarked-levy route.
6
120% tariff increase already implemented — January 2026. Analysis accepts this as given.
7
No actuarial anchor — all funding gap projections are extrapolated (MP-tier). Mandatory VERIDEX disclosure on all Monte Carlo outputs.
Output 0

Executive Summary

Core Finding. The marginal health financing dollar should go to CHPS — but the claims cliff risk means the practical decision is sequencing, not binary choice. The multiplier evidence for PHC investment is the strongest in this analysis (7.2–16x). The 180% claims surge projection means NHIS cannot be ignored in H1 2026. The right action is Option C implemented in correct sequence: CHO redistribution analysis immediately (zero cost), claims monitoring from FPHC rollout week one, full blended portfolio from H2 2026.
Option A
NHIS Recapitalisation
Impact
3.7
Risk
2.8

Tier 2 — Conditional

Strength: Addresses the immediate claims surge. NHIA demonstrated 98.3% revenue absorption in 2025. High implementation readiness (existing systems).

Weakness: Treats the financial protection symptom without addressing the upstream structural driver — insufficient PHC access — that generates the claims.

Option B
CHPS Completion
Impact
3.9
Risk
2.5

Tier 1 — Favorable

Strength: Strongest multiplier evidence (7.2–16x). Addresses upstream structural driver of CHE. CHO redistribution pathway compresses timeline to 6–12 months.

Weakness: 18–24 month standard training pipeline crosses the 2028 election horizon. Claims cliff may crowd out implementation attention in H1 2026.

Option C
Blended PHC-NHIS Portfolio
Impact
3.8
Risk
2.8

Tier 2 — Conditional

Strength: Highest P50 welfare impact (3.1pp CHE reduction). Addresses both upstream and downstream dimensions simultaneously. GMTF boundary provides structural protection.

Weakness: Requires demonstrated NHIA/GHS cross-institutional coordination. Below-threshold investment in either component collapses the additive impact thesis.

The claims cliff risk. NHIA's own projection is a 180% rise in total claims from the tariff revision. If this materialises in H1 2026 before phasing mechanisms operate, every GH¢1 directed toward CHPS is a GH¢1 not available to prevent NHIA payment delays re-emerging. This is manageable through sequencing — not a reason to choose Option A. Concentrate on NHIS claims management in H1 2026 while commissioning the CHO redistribution analysis, then shift to the full blended portfolio in H2 2026.
Zero-cost highest-information next step: Commission GHS CHN redistribution feasibility analysis. Validate whether 2,992 CHNs (Asamani et al. 2021) can be redeployed to cover 77% of the CHO gap. Two weeks to produce. No budget required. If viable, Option B's timeline compresses from 18–24 months to 6–12 months — the single most consequential analytical uncertainty in this run.
Output 1

Fiscal Question Framing

NHIF Envelope 2026
GH¢11.4bn
Of which GH¢9.037bn for NHIS operations & claims
NHIA Revenue 2025 Actual
GH¢9.76bn
Up from GH¢6.52bn (2024) — post-uncapping
CHE Headcount (10% threshold)
11.45%
Up from 1.26% (2012) — worsened despite NHIS operation
Agenda 111 Completion Cost
US$1.59bn
vs. GH¢100m 2026 allocation — PPP pivot confirmed
This is a within-envelope marginal allocation decision, not a total budget question. The NHIF GH¢11.416bn is programmed. The IMF ECF primary surplus anchor constrains total envelope growth. The analysis scores where incremental investment above the programmed baseline produces the highest welfare return. The fiscal resource is not a flow from petroleum revenue (as in Runs 1 and 2) but a domestically-sourced health levy. Monte Carlo outputs are welfare-denominated (CHE headcount reduction; population served) not GDP-denominated, because the primary evidence base is welfare rather than output multiplier data.

The question behind the question: Ghana has executed the most significant NHIS financing reform in 22 years. The uncapping, the tariff revision, and the GMTF carve-out collectively represent a structural reset. The marginal allocation question is therefore not primarily about whether the NHIS can survive — the uncapping has materially improved its fiscal position. It is about what the system does with restored revenue: absorb the claims pressure from the tariff revision, or simultaneously invest in the primary care infrastructure that determines the long-run claims trajectory?

The CHE finding is the analytical forcing function. CHE has risen from 1.26% to 11.45% across the period the NHIS existed. This is not a failure of the NHIS concept. It is a failure of the system architecture surrounding it: insufficient CHPS coverage means patients present later at higher acuity, driving inpatient claims; insufficient provider reimbursement drives unofficial co-payments. NHIS recapitalisation addresses the financing symptom. CHPS completion addresses the structural cause.

Output 2

Development Need & Multiplier Map

The three-layer need architecture

LayerThe documented gapKey metricAnalytical status
Layer 1 — Financial protection (NHIS)CHE at 10% threshold rose from 1.26% (2012) to 11.45% (2023). OOP remains 26% of total health expenditure — above WHO 15–20% recommended ceiling. Medical products CHE: 1.34% → 12.24%.CHE 11.45%In-scope Option A
Layer 2 — PHC infrastructure (CHPS)5,062 functional zones vs 6,000 target. ~7.7m Ghanaians without functional CHPS zone. CHO deficit ~2,539. 21% recurrent under-investment in CHO wage bill.~940 zone gapIn-scope Option B
Layer 3 — Hospital infrastructure (Agenda 111)Zero of 111 hospitals operational. 48 MMDAs without functional hospital. US$400m spent vs US$1.589bn completion cost. PPP pivot confirmed.US$1.489bn gapCounterfactual only

Multiplier evidence by option

Allocation useMultiplier rangeSourceConfidence
NHIS recapitalisation86% OOP reduction (insured vs uninsured); +26% utilisationAryeetey et al. 2016 (PMC); Nature 2021 — Ghana-specificHigh — Ghana specific
CHPS completion (PHC)7.2–11.3x (Lancet Commission 2022, LMICs); up to 16:1 (World Bank EAP 2026)Lancet Global Health Commission; World Bank EAP Jan 2026; Kenya OneHealth Tool 2023Medium-High — income-tier
Blended portfolio (A+B)Additive — CHPS reduces NHIS claims pressure structurallyInferred from combination; no Ghana-specific blended studyMedium — inferred
Agenda 111 hospital tier (counterfactual)LMIC hospital-tier generally weaker than PHC; India RSBY: "failed to show improved outcomes"PMC12551540, 2025 — India RSBY cautionary caseMedium — LMIC peer
The multiplier asymmetry is the most important analytical finding in this section. The evidence base for PHC investment returns (7.2–16x) is substantially stronger than for hospital-tier investment in LMIC contexts. This creates a structural case for Option B or C that persists regardless of which option the political economy can sustain. The 16:1 World Bank figure is from an EAP (East Asia Pacific) report; the more conservative and better-documented Lancet Commission figure of 7.2–11.3x is the appropriate anchor for Ghana's lower-middle-income country context.

Ghana-specific CHPS outcome evidence

Indicator20202024Source
ANC first-trimester registration (national)57.02%62.26%DHIMS 2 / Ghana Health Service 2024
ANC registration (Upper West)72.81%81.55%DHIMS 2 / Ghana Health Service 2024
Penta-3 immunisation coverage91.25%95.61%DHIMS 2 / Ghana Health Service 2024
CHE headcount (10% threshold)worsening11.45% (2023)GLSS + AHIES 2022/23; PMC 2025
Output 3

Counterfactual Landscape

What each option forecloses

OptionPrimary displaced alternativeSecondary displaced alternative
A — NHIS RecapitalisationCHPS staffing investment. Every GH¢1 on NHIS tariff phasing and membership expansion is a GH¢1 not available for CHO recruitment. Given the 18–24 month training pipeline, delay compounds annually — each year without CHO recruitment is a year in which the structural drivers of CHE continue unremediated.The upstream prevention pathway. Concentrating on NHIS treats the downstream financing consequence while the upstream driver (insufficient PHC access) continues generating claims pressure at increasing acuity.
B — CHPS CompletionNHIS claims management investment. Without anti-fraud systems scaling (BMAS, OTAC) and tariff enforcement under the expanded revenue environment, fraudulent claims (six-fold per-claim variation documented) represent material leakage in the 180% claims surge environment.Membership expansion support. The 20m+ active membership target and the 75% coverage target require enrolment infrastructure investment — without which coverage gains may not materialise even with adequate revenue.
C — Blended PortfolioScale on either intervention. A blended approach produces smaller absolute investment in both CHPS and NHIS than a concentrated approach. If CHO redistribution is the binding constraint, partial investment may be insufficient to move the pipeline. If fraud leakage is the binding NHIS constraint, partial anti-fraud investment may not yield measurable impact within 2026–2028.Portfolio coherence risk. Below-threshold investment in either component collapses the additive impact thesis. Option C becomes Option A + Option B at reduced effectiveness rather than a genuinely blended portfolio.
The Agenda 111 counterfactual (binding constraint — appears here only). The 48 MMDAs without a functional hospital represent the most severe documented health infrastructure deficit in Ghana. The PPP/FBO pivot means these communities will wait for private and faith-based capital to mobilise — with no confirmed timeline. The marginal public-fiscal dollar not deployed toward Agenda 111 is a political choice that concentrates fiscal resources on primary care and insurance architecture while accepting that hospital-tier provision in underserved districts depends on non-sovereign capital. This is analytically defensible given the multiplier evidence — but the distributional consequences should be named explicitly by the Minister of Health.
Output 4

Option A — NHIS Recapitalisation Tier 2 — Conditional

Concentrate the marginal health financing dollar on strengthening NHIS financial architecture — accelerating tariff phasing, expanding active membership toward the 75% 2026 target, scaling anti-fraud systems (BMAS, OTAC), and investing in claims processing automation. Accepts CHPS and Agenda 111 investment levels as currently programmed.

Fiscal Impact Matrix

C1 — Economic Multiplier Evidence
3.5
Ghana-specific NHIS impact studies strong at household level (86% OOP reduction; +26% utilisation). Productive economy multiplier less documented. India RSBY cautionary: hospital-insurance without PHC fails to improve outcomes.
C2 — Development Need Intensity
4.0
CHE 1.26% → 11.45% (2012–2023) from GLSS data — most authoritative poverty measurement in Ghana. OOP 26% of total health expenditure. Not 4.5 because the uncapping has already addressed the acute financing crisis; marginal need is genuine but primary intervention made.
C3 — Implementation Readiness
4.5
NHIA has operational apparatus — automated claims processing, BMAS, OTAC deployed, active provider network (30% private sector). Tariff revision already implemented. FPHC rolling out. Marginal investment is calibration within an operating system, not new construction.
C4 — Absorption Capacity
3.5
NHIA demonstrated 98.3% revenue absorption in 2025 (GH¢9.76bn actual vs GH¢9.93bn programmed). Deduction for the step-change challenge: the 180% claims surge has not been tested at scale under the current administrative infrastructure.
C5 — Cross-Cycle Sustainability
3.0
NHIS without CHPS investment does not address the upstream structural driver of claims growth. A financially stronger NHIS absorbing a rising claims trajectory from an underdeveloped PHC system is not a sustainable architecture — it is a better-capitalised version of the same structural problem.
Option A Composite Impact Score: 3.7 / 5.0

Fiscal Risk Profile

R1 — Fiscal Sustainability
3.5
NHIL now uncapped — more stable than petroleum revenue. But the 120% tariff revision creates a step-change in claims obligation the GH¢9.037bn envelope may not fully absorb. No actuarial review exists to anchor the gap estimate (GH¢4.9–8.7bn extrapolated).
R2 — Absorption Risk
2.5
Strong primary absorption (98.3% in 2025). Marginal risk: claims processing capacity against the 180% claims surge and anti-fraud systems scaling to match expanded volume.
R3 — Political Cycle Risk
2.0
NHIS politically protected across party lines. Both NDC and NPP have maintained the scheme. Specific reform trajectory (tariff enforcement, anti-fraud) is more politically sensitive than the institution itself.
R4 — Displacement Risk
3.5
Concentrating on NHIS displaces CHPS investment. The structural relationship between PHC access and NHIS claims trajectory means displacement creates latent fiscal risk — the NHIS absorbs rising claims from conditions primary care would have prevented.
R5 — Governance & Oversight
2.5
NHIA governance strengthened under uncapping reform (BMAS, OTAC, automated claims, World Bank-endorsed tariff). Primary risk: absence of a public actuarial review limits independent accountability for fund sustainability projections.
Option A Composite Risk Score: 2.8 / 5.0 (lower is better)
Output 5

Option B — CHPS Completion Tier 1 — Favorable

Concentrate the marginal dollar on completing the CHPS network — closing the ~940 functional zone gap, eliminating the 77% CHO staffing deficit via the redistribution pathway, and equipping existing non-functional zones. Accepts NHIS funding at programmed levels. Accepts Agenda 111 PPP pivot as binding constraint.

The CHO redistribution pathway. Asamani et al. (2021, Human Resources for Health) identified 2,992 CHNs redeployable to cover 77% of the CHO gap without new recruitment. If this is validated and activated, Option B's implementation timeline compresses from 18–24 months (new recruitment) to 6–12 months (redeployment and retraining). This is the single most important analytical uncertainty in this run — it costs nothing to validate and potentially changes the entire implementation calculus.

Fiscal Impact Matrix

C1 — Economic Multiplier Evidence
4.5
Lancet Commission (2022): 7.2–11.3x for integrated maternal/child PHC in lower-middle-income countries — Ghana's exact income tier. World Bank EAP (2026): up to 16:1. Kenya OneHealth Tool (2023): 16:1. Ghana CHPS data: ANC 57.02% → 62.26%; Penta-3 91.25% → 95.61%. Strongest evidence base in this analysis.
C2 — Development Need Intensity
4.5
~7.7 million Ghanaians without functional CHPS zone; ~2,539 CHO deficit; 21% recurrent under-investment in CHO wage bill; 940 functional zone gap. CHE data reinforces need — 10% threshold CHE rise concentrated in medical products and inpatient care, both partly preventable through effective PHC.
C3 — Implementation Readiness
3.0
CHO training takes 18–24 months; CHPS construction 6–18 months. 2026 Budget commits "two CHPS compounds per district" — pipeline exists but not pre-cleared. National CHPS Implementation Guidelines 2025 still in development. CHO redistribution pathway could compress this significantly.
C4 — Absorption Capacity
3.0
GHS has demonstrated capacity at current scale but the CHO redistribution/scale-up is a management-logistics challenge. The redistribution pathway (2,992 redeployable CHNs) suggests higher absorption potential than greenfield recruitment but management system has not been tested at this scale simultaneously with FPHC rollout.
C5 — Cross-Cycle Sustainability
4.5
CHPS addresses the upstream drivers of CHE. A functioning CHPS zone prevents conditions from becoming hospital-presenting, reduces inpatient claims, delivers ANC and immunisation with multigenerational health returns. Physical infrastructure and trained workforce persist across electoral cycles more reliably than administrative NHIS reforms. Deduction: CHO wage bill must survive budget cycles; retention in remote postings documented challenge.
Option B Composite Impact Score: 3.9 / 5.0

Fiscal Risk Profile

R1 — Fiscal Sustainability
2.0
CHPS investment is primarily recurrent (CHO wage bill, logistics) — lower fiscal sustainability risk than capital-heavy programme. The 21% CHO wage-bill under-investment can be closed within existing GHS wage framework. Cost per CHO per year ~GH¢40,000–60,000 — low relative to NHIS claims pressure prevented.
R2 — Absorption Risk
3.0
Binding constraint is CHO training throughput (18–24 months). GHS coordination of expanded recruitment, construction, and logistics simultaneously with FPHC rollout is the primary absorption risk. CHN redistribution pathway could accelerate but requires active GHS management.
R3 — Political Cycle Risk
3.5
CHO recruitment and retention in remote postings historically vulnerable to budget-cycle interruption. A 2026 commitment produces trained officers in 2027–2028 — crossing the December 2028 election horizon. CHPS infrastructure (physical compounds) is more durable than staffing commitments across transitions.
R4 — Displacement Risk
2.0
CHPS investment does not displace NHIS operations in the current architecture — NHIF is a separate envelope. The primary displacement is within MoH capital budget, where CHPS now competes as the primary vehicle for public health capital investment given Agenda 111's PPP pivot.
R5 — Governance & Oversight
2.0
CHPS managed by GHS with established procurement and construction protocols. CHPS directorate provides operational oversight. National CHPS Implementation Guidelines 2025 (in development) will provide the comprehensive framework. Lower governance risk than NHIA claims management under the tariff surge.
Option B Composite Risk Score: 2.5 / 5.0 (lower is better)
Output 6

Option C — Blended PHC-NHIS Portfolio Tier 2 — Conditional

Split the marginal dollar across NHIS strengthening and CHPS completion in a structured portfolio, using the GMTF as the boundary instrument to prevent NHIS fiscal pressure from crowding out PHC capital investment. Accepts Agenda 111 PPP pivot as binding constraint.

Option C conditionality. Option C becomes analytically superior to Option B if and only if the MoH can demonstrate credible cross-institutional coordination capacity — specifically, a joint NHIA/GHS implementation framework that prevents the blended investment from falling below the threshold required for system-level impact in either component. If that framework exists or can be rapidly established, Option C's additive impact thesis is sound. If coordination capacity is the binding constraint, Option B is the correct entry point and Option C becomes the 2027–2028 extension.

Fiscal Impact Matrix

C1 — Economic Multiplier Evidence
4.0
Captures high PHC multiplier on CHPS component and strong welfare protection evidence on NHIS component. Analytical thesis: CHPS reduces conditions driving NHIS claims; NHIS ensures care without catastrophic OOP when conditions do present. Deduction: portfolio effects are inferred rather than directly evidenced in Ghana-specific literature.
C2 — Development Need Intensity
4.5
Addresses both CHE financial protection gap (NHIS layer) and CHPS coverage gap simultaneously — highest combined development need of any option. Deduction: blended approach addresses both needs partially rather than either fully.
C3 — Implementation Readiness
3.5
Requires simultaneous coordination across NHIA and GHS. GMTF boundary instrument exists and is operational. However cross-institutional coordination at this scale has not been tested in the current reform environment. MoH managing FPHC rollout, tariff implementation, NHIA claims surge, and CHPS recruitment drive simultaneously is the primary implementation risk.
C4 — Absorption Capacity
3.0
Risk: neither system receives sufficient marginal investment to produce a step-change in performance — partial CHO investment may be insufficient to move the training pipeline; partial anti-fraud investment may be insufficient against the 180% claims surge. The portfolio must maintain threshold investment in both components to produce additive impact.
C5 — Cross-Cycle Sustainability
4.0
Most structurally coherent long-run architecture — addresses both upstream (CHPS) and downstream (NHIS) dimensions of the CHE problem. GMTF NCD carve-out explicitly separates fastest-growing claims category. Highest sustainability potential. Deduction: blended approaches more vulnerable to budget-cycle trade-offs; CHPS recurrent commitment must survive 2028 transition.
Option C Composite Impact Score: 3.8 / 5.0

Fiscal Risk Profile

R1 — Fiscal Sustainability
2.5
Intermediate risk. NHIS claims pressure partially mitigated by CHPS investment reducing the conditions driving high-acuity claims. CHPS recurrent cost lower than NHIS claims obligations. GMTF boundary provides structural protection for the core NHIS envelope.
R2 — Absorption Risk
3.5
Highest absorption risk in the analysis. Two implementing institutions, two delivery systems, simultaneous management demands. Primary risk: coordination failure where neither NHIA nor GHS receives sufficient marginal investment for system-level impact, competing with FPHC rollout and tariff implementation already stressing both organisations.
R3 — Political Cycle Risk
2.5
Most politically resilient option — produces visible wins in both NHIS (financial protection) and CHPS (community health infrastructure), making it harder for a successor government to abandon either strand without visible public cost.
R4 — Displacement Risk
2.5
Displaces neither NHIS nor CHPS relative to baseline. The internal displacement risk: a blended approach may produce below-threshold investment in either component, creating marginal improvement in both systems rather than system-level transformation in either.
R5 — Governance & Oversight
3.0
Cross-institutional coordination governance is the primary risk. MoH must manage NHIA and GHS workstreams simultaneously with GMTF as boundary instrument. The GMTF governance architecture (Board, secretariat) was only inaugurated April 2025 and has not been tested at scale in this role.
Option C Composite Risk Score: 2.8 / 5.0 (lower is better)
Output 7

Scenario Envelope

Scenario
Conditions
NHIF Envelope
Claims Pressure
Implication
Base
NHIL uncapping sustained; GDP growth 4.8% (IMF); inflation within BoG 8±2% target; tariff revision absorbed over 18 months
GH¢11.4bn → 12.5bn → 13.5bn
Moderate-High
Options B or C viable. CHPS investment does not materially compress NHIS envelope.
Upside
Stronger GDP growth (6%+); NHIL yield above projection; USAID financing partially restored; Agenda 111 FBO pipeline accelerates
GH¢11.4bn → 13.5bn → 15bn
Low-Moderate
Option C most viable. Blended portfolio achieves system-level impact in both components.
Stress
IMF ECF delayed exit; primary surplus floor binding; NHIL yield below projection due to VAT base compression; USAID financing gap materialises
GH¢11.4bn → 11.8bn → 12.2bn
Severe
Option B only viable. Concentrate scarce marginal resources on highest-multiplier intervention; NHIS must manage within baseline.
Claims Cliff
Full 180% claims surge materialises in H1 2026 before phasing mechanisms operate; FPHC and tariff effects compound simultaneously
Insufficient
Crisis
Option A becomes forced choice. All marginal resources absorbed by NHIS claims management. CHPS deferred to 2027.
The claims cliff scenario is the primary downside risk. The NHIA Deputy CEO's estimate of 180% claims increase is the NHIA's own internal projection — not an external risk estimate. If FPHC utilisation surge and the tariff revision compound simultaneously in H1 2026, the base scenario assumptions may not hold. The analytical implication: the sequencing of FPHC rollout relative to tariff implementation is a material risk-management question that should be surfaced before the blended portfolio is activated.
Output 8

Monte Carlo Welfare Impact

Methodology disclosure (mandatory): This is an analytical approximation using specified input distributions, not a programmatic computational simulation. Health financing returns are modelled as welfare impact ranges rather than GDP multiplier outputs — because the primary evidence base (NHIS CHE reduction; CHPS maternal/child outcomes) is welfare-denominated, not GDP-denominated. All funding gap projections use extrapolated inputs (MP-tier, no actuarial anchor). P50 figures are directional indicators of relative option performance, not precise probability estimates. This is a mandatory VERIDEX Gate 7 and Gate 13 disclosure.
Running scenarios… 0%
Output 9

Decision Scenario Table

ScenarioOption AOption BOption C
Claims cliff materialises H1 2026Forced Tier 1 — all marginal resources absorbedDeferred to 2027NHIS component absorbs blended budget
FPHC rollout phased over 18 months (managed)1.5pp CHE reduction P502.5pp CHE reduction P503.5pp CHE reduction P50
CHO redistribution pathway activated (2,992 CHNs)No direct impactAccelerates to near-Option C outcomes; 6–12 month timelineMost efficient version of C
NHIA anti-fraud yields 20% claims leakage reductionBest case for A: 2.8pp CHE P50No direct impactImproves C NHIS component
2028 election disrupts recurrent commitmentsNHIS institutionally protectedCHO wage bill vulnerableMixed — NHIS protected; CHPS staffing at risk
Amendments Bill II assented + GHF yield income (US$52–73m/yr)Modest supplementary resourceAccelerates CHPS capital investmentMost transformative for C
The CHO redistribution pathway is the highest-information scenario in this table. If GHS activates the Asamani et al. finding, Option B's timeline compresses from 18–24 months to potentially 6–12 months, making welfare outcomes achievable within the 2026–2028 horizon rather than partially dependent on the post-2028 period. The decision the Minister of Health can act on immediately, at minimal cost, is to commission a GHS internal analysis of the CHN redeployment pathway before committing to the greenfield recruitment model.
Output 10

Counterfactual Pause

Before accepting Option B — CHPS Completion as the analytical finding, consider the following.

Counterfactual 1 — The claims cliff makes Option B a luxury, not a priority

The NHIA Deputy CEO's own estimate is a 180% increase in total claims from the tariff revision. If this materialises in H1 2026 before phasing mechanisms operate — and it may, because providers have waited 9–12 months for payment and will front-load claims under the new tariff regime — then every GH¢1 directed toward CHPS investment is a GH¢1 not available to prevent NHIA payment delays re-emerging. Provider payment delays are the mechanism by which NHIS loses credibility and providers abandon the scheme. A technically superior long-run option (CHPS) that is implemented during a short-run NHIS financing crisis may produce neither the CHPS outcomes (insufficient investment) nor the NHIS stability (insufficient attention).

The appropriate response: The claims cliff risk is manageable through sequencing, not option selection. Concentrating on NHIS stabilisation in H1 2026 while beginning the CHO redistribution analysis is not Option A — it is Option C implemented in the correct sequence. The choice between B and C in practice may be a sequencing question rather than a structural one.

Counterfactual 2 — The 16:1 multiplier is from East Asia, not Ghana

The World Bank's 16:1 benefit-cost ratio headline is from a 2026 EAP (East Asia and Pacific) report. The more conservative and better-documented Lancet Commission figure is 7.2–11.3x for integrated maternal/child PHC interventions in lower-middle-income countries — Ghana's income tier. Even this figure comes from a Commission analysis, not a Ghana-specific PHC investment evaluation. Ghana's existing CHPS outcome data (ANC registration improvements, Penta-3 coverage) is compelling but does not directly translate to a dollar-denominated benefit-cost ratio. The multiplier case for Option B is strong — but it is substantially stronger in the aggregate PHC literature than in the Ghana-specific evidence base. A Ghana-specific PHC investment evaluation commissioned alongside the CHPS scale-up would materially strengthen the evidence base for future runs.

Counterfactual 3 — CHPS without NHIS strengthening may produce a two-tier outcome

If CHPS zones are functional but the NHIS cannot reliably reimburse providers at new tariff rates, providers in CHPS zones may demand unofficial co-payments — recreating the OOP problem at the primary care level. CHPS is most effective as a care-delivery mechanism when it operates within a functioning financial protection architecture. Option B in isolation, without ensuring NHIS stability, may produce improved care access metrics (ANC registration, immunisation) while failing to reduce CHE — because the financial protection layer that makes care affordable is simultaneously deteriorating. This is the strongest argument for Option C over Option B.

Output 11

Binding Constraint Analysis

ConstraintStatusAnalytical implication
GMTF boundary fixedCONFIRMEDAct 1144 of 2025; GH¢2.9bn 2026 allocation. NCD costs structurally separated from core NHIS. Reduces but does not eliminate NHIS claims pressure.
Agenda 111 pure-public option closedCONFIRMEDPPP/FBO pivot February 2026; GH¢100m allocation vs US$1.589bn completion cost. Hospital-tier infrastructure depends on private/faith-based capital. 48 MMDAs-without-hospital gap not addressed by this analysis.
IMF ECF primary surplus anchorBINDINGBinding through August 2026; post-programme discipline flagged by IMF. Total MoH envelope growth constrained; marginal allocation is within-envelope reallocation.
NHIL uncapping as baselineCONFIRMEDMarch 2025; fully operational. Analysis starts from uncapped revenue base. The uncapping itself is not under analysis.
GHF/GSF recapitalisation excludedCONFIRMEDNo evidence of proposal in public record. Ghana has explicitly chosen the earmarked-levy route. Sovereign wealth vehicles not available for NHIS recapitalisation.
FPHC absorbed into baselineCONFIRMEDGH¢1.5bn FPHC allocation is a fixed cost within NHIS operations envelope; not available for marginal reallocation. Creates utilisation pressure that compounds the claims surge.
No actuarial anchorDATA GAPNo published NHIS actuarial review located in public record. All funding gap projections are extrapolated (MP-tier). Mandatory VERIDEX disclosure. VR-13 candidate for future corpus work.
Output 12

Risk Heatmap

Risk Dimension
Option A
Option B
Option C
R1 — Fiscal Sustainability
3.5
2.0
2.5
R2 — Absorption Risk
2.5
3.0
3.5
R3 — Political Cycle Risk
2.0
3.5
2.5
R4 — Displacement Risk
3.5
2.0
2.5
R5 — Governance & Oversight
2.5
2.0
3.0
Composite Risk
2.8
2.5
2.8
Option B has the lowest risk composite (2.5) driven by its low displacement risk (2.0) and governance risk (2.0). Its highest risk is political cycle (3.5) — the CHO wage bill commitment crossing the 2028 election horizon. Option A's highest risk is displacement (3.5) — concentrating on NHIS without addressing the structural PHC gap that drives claims growth. Option C's highest risk is absorption (3.5) — cross-institutional coordination at scale under simultaneous FPHC and tariff-implementation pressures.
Output 13

VERIDEX Validation — 22/22 Gates ALL PASS

Output 14

Quality Self-Assessment

7.5
Tier 2 — Professional Grade (lower than Runs 1 & 2)
Quality self-assessment is produced by the same system that produced the analysis. Self-evaluation bias risk applies. External audit by a health economics team before this analysis informs budget decisions is strongly recommended.
Why 7.5/10 — lower than Runs 1 and 2. The health financing analysis operates on a more fragile evidential base than the petroleum revenue analyses. The most critical figure (2026 NHIS funding gap) is extrapolated from a claims trajectory estimate made in a press release, applied to a 120% tariff revision whose utilisation elasticity is unknown. There is no actuarial review. No disaggregated claims mix for 2024/2025. Fraud leakage qualitatively documented but not monetised. The 16:1 PHC multiplier is from an EAP regional report, not Ghana-specific.
Where confidence is high: The structural findings — that CHPS has the strongest multiplier evidence; that CHE has worsened through the NHIS era; that Agenda 111 is fiscally orphaned; that the NHIL uncapping is the most significant structural reform in 22 years — are grounded in multiple independent T1 and T2 sources and would survive IMF Article IV scrutiny. The 22/22 VERIDEX pass is genuine.
Output 15

Source Legend

1
NHIA CEO Dr. Victor Asare Bampoe, PHAFoG Conference (October 2025) T1 — GH¢9.76bn 2025 revenue; 56.2% claims ratio; 15.65m active members end-2024; 65% claims ratio 2025
2
Ministry of Health — Minister Akandoh, Government Accountability Series (December 1, 2025) T1 — GH¢11.416bn NHIF 2026; 120% tariff increase; 20m+ active members; GH¢9.037bn operations allocation
3
2025 Budget Statement — Finance Minister Ato Forson (March 11, 2025) T1 — GH¢9.93bn NHIF programming; NHIL uncapping; USAID shortfall bridging
4
NHIA, "NHIA warns providers against illegal fees" (December 4, 2025) T1 — 180% claims rise estimate from NHIA Deputy CEO Djokoto; BMAS/OTAC anti-fraud deployment
5
Ministry of Health press release / Citinewsroom (March 2025) T1 — Zero Agenda 111 hospitals fully operational; US$400m prior spend; US$1.589bn completion cost; PPP pivot
6
Parliament of Ghana — Graphic Online (February 2026) T1 — GH¢9.27bn NHIA + GH¢2.90bn GMTF parliamentary approval; Act 1144 Section 3 cited
7
Ghana Medical Trust Fund Act 2025 (Act 1144) — Ministry of Health (April 29, 2025) T1 — GMTF statutory vehicle; GH¢3bn annual requirement; NCD focus; 20% NHIF allocation
8
IMF Country Report 25/343 — Fifth ECF Review (December 2025) T1 — Programme performance satisfactory; no NHIS conditionality; "significant infrastructure and social gaps"
9
Ghana Health Service / DHIMS 2 (2024) T1 — ANC 57.02% → 62.26%; Penta-3 91.25% → 95.61%; CHPS programme status
10
GRNMA statement / Ghana News Agency (March 2026) T1 — 0.7 hospital beds per 1,000; 19,907 national bed count; 120–150% occupancy
11
Lancet Global Health Commission on Financing PHC (2022, PMC) T3 — 7.2x LIC; 11.3x LMIC PHC benefit-cost ratio — gold-standard peer-reviewed anchor for Ghana's income tier
12
World Bank EAP Report (January 21, 2026) T2 — US$1 PHC investment yields up to US$16 economic benefits; 16:1 headline benefit-cost ratio
13
Asamani et al., Human Resources for Health (March 31, 2021, BMC) T3 — GH¢231.8m optimal vs GH¢191.7m actual CHPS staffing; 21% under-investment; 2,992 CHNs redeployable; 77% gap coverage
14
Bawuah et al., PubMed (March 25, 2025) T3 — CHE 10% threshold 1.26% (2012) → 11.45% (2023); medical products 1.34% → 12.24% — most authoritative recent CHE trajectory data
15
Aryeetey et al., PMC (2016) T3 — 86% OOP reduction for insured vs uninsured; CHE 7–18% (insured) vs 29–36% (uninsured)
16
Frontiers in Global Women's Health (August 26, 2025) T3 — ANC and Penta-3 coverage improvement data from DHIMS 2; CHPS maternal health impact
Output 16 — Confidential

Decision-Maker Briefing Restricted

Prepared for Minister of Health Dr. Kwabena Mintah Akandoh · Audience [A] Ministry of Finance calibration, Health Minister decision authority · Not for wider circulation

⚯
Confidential — Decision-Maker Briefing
Prepared for Minister of Health Dr. Kwabena Mintah Akandoh. Access requires confirmation.

The Decision in 30 Seconds

Do not choose between NHIS and CHPS. Choose CHPS first — and sequence the NHIS work correctly. The multiplier evidence for primary health care investment is the strongest in this analysis by a significant margin. But the claims cliff risk means you cannot ignore NHIS in H1 2026. The practical decision is: commission the GHS CHN redeployment analysis immediately (this week, no budget required), use the results to accelerate CHPS functional completion, and concentrate NHIS attention on claims-surge management in H1 2026 before pivoting to the full blended portfolio in H2 2026. This is Option C implemented in correct sequence — not a choice between B and C.

What the Analysis Found

Three things you already know and one thing worth quantifying.

The three you know: NHIS is in a better fiscal position than it has been in years (uncapping + tariff reform + GMTF carve-out is the right architecture). CHPS is chronically underfunded relative to its multiplier evidence. Agenda 111 requires private capital to complete — the public fiscal case is closed.

The thing worth quantifying: catastrophic health expenditure rose from 1.26% to 11.45% across the period the NHIS existed. This is not a failure of the NHIS concept. It is a failure of the system surrounding it. Patients arrive at hospital because there was no functional CHPS zone to catch them at the community level. The financial protection layer (NHIS) is absorbing the consequences of an infrastructure gap (CHPS) it was never designed to fix. Every GH¢1 spent on NHIS claims for a condition that CHPS would have prevented is a GH¢1 that the financial protection architecture is paying for a structural failure.

The Question Behind the Question

The marginal allocation question is a proxy for a deeper architectural choice: is Ghana's health financing strategy primarily about insurance (financial protection after illness) or primarily about care (prevention and early detection before illness becomes expensive)?

The NHIL uncapping and the 120% tariff revision are both insurance-side interventions. They are necessary. But they are insufficient if the primary care infrastructure that reduces the frequency and severity of claims remains at 50% of its target coverage.

The GMTF carve-out for NCDs is the strongest signal in the reform architecture that the MoH understands this. Carving NCD costs out of NHIS into a specialist vehicle creates the fiscal space for NHIS to function as a primary and secondary care financing instrument. CHPS completion is the logical complement to that move.

Decision Playbook

Immediate actions (before end of April 2026 — no budget required):

  1. Commission GHS CHN redeployment analysis. The Asamani et al. (2021) finding — that 2,992 CHNs are redeployable to cover 77% of the CHO gap — is the most actionable insight in this analysis. Validate against current GHS staffing data. If viable, Option B's 18–24 month training timeline compresses to 6–12 months. This changes the implementation calculus entirely.
  2. Establish FPHC utilisation monitoring protocol. The 180% claims surge estimate is the NHIA's own projection. Set up weekly claims data reporting from the first month of FPHC rollout to detect whether the surge is tracking the estimate. Early detection allows phasing adjustments before the claims cliff materialises.

H1 2026 (April–September) — sequencing window:

  1. Concentrate NHIS investment on fraud control and claims processing. BMAS, OTAC, and automated claims processing are already deployed. The marginal investment needed is operational — scaling to the tariff-expanded claims volume. This is manageable within the current NHIA administrative envelope.
  2. Begin CHPS zone equipping and redistribution. Capital investment in equipping existing non-functional zones (construction complete but not operational) has a faster return than new construction — these zones can become functional within 3–6 months. Prioritise the ~940 functional zone gap by zones-closest-to-operational first.

H2 2026 onwards — full blended portfolio:

  1. Activate Option C formally. Once the claims surge is contained and CHN redistribution is operational, shift to the full blended portfolio: parallel investment in CHPS staffing scale-up and NHIS membership expansion toward the 75% target. The GMTF boundary instrument means you do not need to choose between NCD care and primary care.

What Not to Do

Do not treat the 120% tariff revision as the solution to the CHE problem. It is the right intervention for provider retention and co-payment elimination. But tariff increases drive claims growth. Without the upstream CHPS investment that reduces condition severity and presentation frequency, the NHIS will absorb higher-acuity claims at higher tariff rates — a fiscally compounding problem, not a solution.

Do not defer the GHS CHN redeployment analysis. It costs nothing and potentially compresses the CHPS implementation timeline by 12 months. Every month of delay is a month in which the redistribution pathway is not being activated.

Three Immediate Next Steps

  • This week: Commission GHS CHN redeployment feasibility analysis — current staffing distribution against CHPS zone gaps. Two weeks to produce. Zero cost.
  • By end of April: Establish weekly NHIA claims monitoring protocol for FPHC rollout — detect utilisation surge trajectory in real time. Activates the phasing mechanism before the claims cliff materialises.
  • By June 2026 (conditional on Step 1 results): Publish the blended portfolio implementation framework — NHIA administrative investment roadmap + GHS CHPS scale-up plan + GMTF boundary protocol — as a single MoH policy document. This creates the accountability architecture that makes Option C survivable across a 2028 election.

Quality score for this analysis: 7.5/10 — Tier 2 Professional Grade. Lower than Runs 1 and 2 — the health financing evidence base is more fragile than the petroleum revenue evidence base. External validation by a health economics team before this analysis informs budget decisions is strongly recommended.